• Nicotinamide Riboside Chloride (NIAGEN): Redefining Assay Pr

  2026-04-21

  Explore how Nicotinamide Riboside Chloride (NIAGEN) enables transformative precision in metabolic dysfunction and neurodegenerative disease models. This article delivers a critical, evidence-driven roadmap for deploying NIAGEN to optimize cellular assays beyond current paradigms.

• EZ Cap EGFP mRNA 5-moUTP: Standards for Fluorescent Reporter

  2026-04-20

  EZ Cap™ EGFP mRNA (5-moUTP) delivers enhanced green fluorescent protein expression with high stability and minimized immunogenicity. This capped and chemically modified mRNA reagent, supplied by APExBIO, is benchmarked for robust translation efficiency and reproducibility in both in vitro and in vivo imaging workflows.

• Iptacopan Monotherapy in PNH: Rapid Hemolysis Control and Hb

  2026-04-20

  This open-label phase 2 study establishes Iptacopan (LNP023) as a potent oral, selective factor B inhibitor that rapidly improves hemolytic markers and hemoglobin levels in paroxysmal nocturnal hemoglobinuria (PNH) patients. The findings demonstrate clinically meaningful, transfusion-free outcomes in treatment-naïve patients, addressing limitations of existing C5 inhibitors and paving the way for more convenient oral therapies.

• JC-1 and the Future of Mitochondrial Health in Precision Onc

  2026-04-19

  This article explores the critical role of JC-1 (5,6-dichloro-2-[(E)-3-(5,6-dichloro-1,3-diethylbenzimidazol-3-ium-2-yl)prop-2-enylidene]-1,3-diethylbenzimidazole iodide) in mitochondrial membrane potential assays, contextualized by emerging research on mitochondrial dynamics in anaplastic thyroid cancer. Through mechanistic insight and actionable protocol guidance, we dissect JC-1’s value in translational workflows and highlight strategic considerations for next-generation apoptosis detection and mitochondrial dysfunction research.

• Troglitazone as a Precision Tool for PPARγ Pathway Dissectio

  2026-04-18

  Unlock the advanced applications of Troglitazone, a potent PPARγ agonist, in dissecting nuclear receptor signaling and tumor microenvironment modulation. This article delivers unique assay guidance and practical insights for type 2 diabetes and anti-tumor research.

• iPSC-Based Drug Screening for Ultrarare Disease Trial Select

  2026-04-17

  This study presents a personalized, induced pluripotent stem cell (iPSC)-based platform to prescreen drug efficacy in patients with ultrarare pathogenic mutations, addressing the clinical challenge of unpredictable treatment responses. By modeling an ultrarare Leigh-like syndrome case, the authors demonstrate that iPSC-derived cells enable the assessment of drug safety and metabolic correction before clinical trial enrollment, potentially improving outcomes in rare disease therapy.

• Decoding Metabolic Flexibility: Strategic Aconitase Assays

  2026-04-16

  This thought-leadership article explores the mechanistic and translational significance of aconitase activity quantification, specifically via the APExBIO Aconitase Activity Colorimetric Assay Kit, in advancing immunometabolic research. Through the lens of recent discoveries in T cell metabolic flexibility, we bridge fundamental insights with actionable strategies for translational and clinical researchers. The article benchmarks assay performance, discusses protocol parameters, and positions aconitase quantification as a fulcrum for high-impact discovery in metabolic disease and immunology.

• Cy5-UTP (Cyanine 5-UTP): Advancing RNA Labeling in Cell Assa

  2026-04-15

  This article explores how Cy5-UTP (Cyanine 5-UTP, SKU B8333) addresses core laboratory challenges in RNA probe synthesis, FISH, and dual-color arrays. Drawing on real-world scenarios and validated parameters, it demonstrates how APExBIO’s offering enhances reproducibility, sensitivity, and workflow reliability for biomedical researchers.

• 2X Taq PCR Master Mix (with Dye): Precision PCR for DNA Repa

  2026-04-14

  Explore how the 2X Taq PCR Master Mix (with dye) advances molecular biology by enabling precise DNA amplification for genotyping, cloning, and DNA repair studies. This article uniquely connects PCR reagent performance with emerging DNA repair mechanisms in cancer research.

• Amitriptyline HCl in Neuropharmacology: Protocols & BBB Mode

  2026-04-13

  Amitriptyline HCl is pivotal for dissecting neurotransmitter receptor dynamics and optimizing blood-brain barrier (BBB) assays. This article guides researchers through best practices, novel model integration, and troubleshooting strategies to maximize reproducibility and translational relevance in CNS drug discovery.

• Plk1 Regulation of p31comet in Mitotic Checkpoint Disassembl

  2026-04-13

  This study uncovers how Polo-like kinase 1 (Plk1) directly phosphorylates p31comet, modulating its role in disassembling mitotic checkpoint complexes. These findings clarify regulatory mechanisms controlling mitotic progression and have implications for the development of Aurora kinase-targeted research tools.

• Nuclear cGAS-TRIM41 Axis Restricts LINE-1 via Chk2-Mediated

  2026-04-12

  This study uncovers a novel mechanism by which nuclear cGAS suppresses LINE-1 (L1) retrotransposition through TRIM41-mediated ORF2p ubiquitination and degradation, a process critically dependent on Chk2-driven cGAS phosphorylation during DNA damage. These findings provide essential insight into genome integrity maintenance and present a new regulatory axis with translational potential for DNA damage response and cancer research.

• RG108 DNA Methyltransferase Inhibitor: Depths of Epigenetic

  2026-04-12

  Explore the advanced mechanisms and unique assay considerations of RG108, a potent DNA methyltransferase inhibitor. This article delivers an in-depth scientific analysis and actionable guidance for researchers in epigenetic gene regulation modulation.

• Dasatinib Monohydrate: Transforming Patient-Derived Tumor Mo

  2026-04-11

  Dasatinib Monohydrate (BMS-354825) delivers unmatched kinase inhibition for translational cancer studies, especially where resistance to first-line therapies is a barrier. This guide decodes best practices, troubleshooting, and innovative workflows for integrating Dasatinib in advanced assembloid models and personalized drug screens.

• Naftifine HCl: Precision Workflows for Antifungal Research

  2026-04-11

  Naftifine HCl streamlines targeted antifungal and sterol biosynthesis research with robust, reproducible protocols. This article delivers actionable workflow enhancements, troubleshooting guidance, and cross-domain insights, drawing on both advanced literature and APExBIO’s high-purity offering.

14517 records 1/968 page Next 12345 下5页 Last page